If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.




GSK and CureVac sign mRNA vaccine and therapy deal

Investment of about $300 million up front is latest vote of confidence in mRNA technology

by Ryan Cross
July 23, 2020 | A version of this story appeared in Volume 98, Issue 29


A photo of CureVac’s clinical manufacturing site in Tubingen, Germany.
Credit: CureVac
CureVac’s clinical manufacturing site in Tubingen, Germany

GlaxoSmithKline is the latest big pharma firm to invest in the hot field of messenger RNA (mRNA) vaccines and therapies. GSK has signed a deal potentially worth $1.1 billion with the German biotech company CureVac to research, develop, manufacture, and commercialize up to five mRNA vaccines and mRNA-encoded monoclonal antibodies for infectious diseases.

mRNA vaccines, which encode a viral protein in a string of nucleotides, are faster to design and manufacture than traditional vaccines, based on whole viruses or viral proteins. Companies specializing in mRNA have found themselves in the limelight during the COVID-19 pandemic. The technology is still considered experimental, however, as an mRNA vaccine has yet to be approved.

Support nonprofit science journalism
C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support us:
Donate Join Subscribe

CureVac was among the first companies to work on a vaccine for COVID-19 early this year. It began testing its candidate in a placebo-controlled Phase I study of 168 volunteers in June.

Large, late-stage clinical studies will soon begin for two other mRNA vaccines: one from Moderna and another from Pfizer and the German company BioNTech (see page 4). Sanofi recently invested $425 million in Translate Bio to make mRNA vaccines for infectious diseases. That duo’s COVID-19 vaccine is due to enter clinical testing by the end of the year.

CureVac’s experimental COVID-19 vaccine is not included in the deal with GSK. So far, GSK has not committed to developing a COVID-19 vaccine of its own but is supplying other firms with vaccine-boosting adjuvants.

GSK will pay CureVac more than $130 million in cash and take a 10% stake in the company worth $171 million. It will also pay CureVac about $30 million to reserve space in a manufacturing facility it is building in Germany. CureVac could also earn development and commercial milestone payments worth about $770 million.

CureVac has attracted other investors during the pandemic. The German government put $343 million into the firm in June, and the Qatar Investment Authority chipped in $126 million in July.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.